- Oops!Something went wrong.Please try again later.
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $24 million in its fourth quarter.
The Novato, California-based company said it had a loss of 37 cents per share. Losses, adjusted for non-recurring gains, were $1.34 per share.
The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.06 per share.
The biotechnology company posted revenue of $91.5 million in the period, beating Street forecasts. Seven analysts surveyed by Zacks expected $71.2 million.
For the year, the company reported that its loss narrowed to $186.6 million, or $3.07 per share. Revenue was reported as $271 million.
Ultragenyx shares have climbed 18% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $162.78, more than doubling in the last 12 months.